# A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

> **NCT01685268** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AT13387
- **DRUG:** abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01685268
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685268, "A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01685268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*